Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Brian M Alexander, Eudocia Q Lee, David A Reardon & Patrick Y Wen. (2013) Current and future directions for Phase II trials in high-grade glioma. Expert Review of Neurotherapeutics 13:4, pages 369-387.
Read now
Read now
Tor-Christian Aase Johannessen & Rolf Bjerkvig. (2012) Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Review of Anticancer Therapy 12:5, pages 635-642.
Read now
Read now
Michael Biss & Wei Xiao. (2012) Selective tumor killing based on specific DNA-damage response deficiencies. Cancer Biology & Therapy 13:5, pages 239-246.
Read now
Read now
Nupur N. Gangopadhyay, James D. Luketich, Amy Opest, Carmen Visus, Ernest M. Meyer, Rodney Landreneau & Matthew J. Schuchert. (2011) Inhibition of Poly(ADP-Ribose) Polymerase (PARP) Induces Apoptosis in Lung Cancer Cell Lines. Cancer Investigation 29:9, pages 608-616.
Read now
Read now
Andreas Höglund, Kerstin Strömvall, Yongmei Li, Linus Plym Forshell & Jonas A. Nilsson. (2011) Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle 10:20, pages 3598-3607.
Read now
Read now
Darren Hargrave. (2009) Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. British Journal of Neurosurgery 23:4, pages 351-363.
Read now
Read now
Omar Khan & Mark R Middleton. (2007) The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors. Expert Opinion on Investigational Drugs 16:10, pages 1573-1584.
Read now
Read now
Darren R Hargrave & Stergios Zacharoulis. (2007) Pediatric CNS tumors: current treatment and future directions. Expert Review of Neurotherapeutics 7:8, pages 1029-1042.
Read now
Read now
Nicola Curtin. (2007) Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opinion on Therapeutic Targets 11:6, pages 783-799.
Read now
Read now
Ruth Plummer. (2006) Poly(ADP-ribose) polymerase inhibition and its potential use in malignant melanoma. Expert Review of Dermatology 1:4, pages 599-605.
Read now
Read now
Yan Luo & Joel D Leverson. (2005) New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response. Expert Review of Anticancer Therapy 5:2, pages 333-342.
Read now
Read now
Stefan Peukert & Uwe Schwahn. (2004) New inhibitors of poly(ADP-ribose) polymerase (PARP). Expert Opinion on Therapeutic Patents 14:11, pages 1531-1551.
Read now
Read now
Articles from other publishers (62)
Fumi Higuchi, Hiroaki Nagashima, Jianfang Ning, Mara V.A. Koerner, Hiroaki Wakimoto & Daniel P. Cahill. (2020) Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. Clinical Cancer Research 26:7, pages 1690-1699.
Crossref
Crossref
Steven J Isakoff, Shannon Puhalla, Susan M Domchek, Michael Friedlander, Bella Kaufman, Mark Robson, Melinda L Telli, Véronique Diéras, Hyo Sook Han, Judy E Garber, Eric F Johnson, David Maag, Qin Qin, Vincent L Giranda & Stacie P Shepherd. (2017)
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in
BRCA1
/
2
metastatic breast cancer: design and rationale
. Future Oncology 13:4, pages 307-320.
Crossref
Crossref
Patricia M. LoRusso, Jing Li, Angelika Burger, Lance K. Heilbrun, Edward A. Sausville, Scott A. Boerner, Daryn Smith, Mary Jo Pilat, Jie Zhang, Sara M. Tolaney, James M. Cleary, Alice P. Chen, Lawrence Rubinstein, Julie L. Boerner, Adam Bowditch, Dongpo Cai, Tracy Bell, Andrew Wolanski, Allison M. Marrero, Yiping Zhang, Jiuping Ji, Katherine Ferry-Galow, Robert J. Kinders, Ralph E. Parchment & Geoffrey I. Shapiro. (2016) Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clinical Cancer Research 22:13, pages 3227-3237.
Crossref
Crossref
Karen E. Parrish, Ling Cen, James Murray, David Calligaris, Sani Kizilbash, Rajendar K. Mittapalli, Brett L. Carlson, Mark A. Schroeder, Julieann Sludden, Alan V. Boddy, Nathalie Y.R. Agar, Nicola J. Curtin, William F. Elmquist & Jann N. Sarkaria. (2015) Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Molecular Cancer Therapeutics 14:12, pages 2735-2743.
Crossref
Crossref
M.-C. Chen, B. Zhou, K. Zhang, Y.-C. Yuan, F. Un, S. Hu, C.-M. Chou, C.-H. Chen, J. Wu, Y. Wang, X. Liu, D. L. Smith, H. Li, Z. Liu, C. D. Warden, L. Su, L. H. Malkas, Y. M. Chung, M. C.- T. Hu & Y. Yen. (2015) The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro. Molecular Pharmacology 87:6, pages 996-1005.
Crossref
Crossref
Kim A. Reiss, Joseph M. Herman, Marianna Zahurak, Anthony Brade, Laura A. Dawson, Angela Scardina, Caitlin Joffe, Emily Petito, Amy Hacker-Prietz, Robert J. Kinders, Lihua Wang, Alice Chen, Sarah Temkin, Naomi Horiba, Lillian L. Siu & Nilofer S. Azad. (2015) A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis. Clinical Cancer Research 21:1, pages 68-76.
Crossref
Crossref
Paolo Bironzo & Giorgio Vittorio Scagliotti. (2014) Squamous carcinoma of the lung: still a long and winding road to successful treatment. Lung Cancer Management 3:5, pages 365-368.
Crossref
Crossref
P Znojek, E Willmore & N J Curtin. (2014) Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. British Journal of Cancer 111:7, pages 1319-1326.
Crossref
Crossref
Fan Lin, Mark C. de Gooijer, Eloy Moreno Roig, Levi C.M. Buil, Susan M. Christner, Jan H. Beumer, Thomas Würdinger, Jos H. Beijnen & Olaf van Tellingen. (2014) ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy. Clinical Cancer Research 20:10, pages 2703-2713.
Crossref
Crossref
Corey Speers, Felix Y Feng & Lori J Pierce. (2014) PARP-1 inhibitors and radiotherapy sensitivity: future prospects for therapy?. Breast Cancer Management 3:3, pages 281-296.
Crossref
Crossref
Makiko Tahara, Takeshi Inoue, Futoshi Sato, Yasuyuki Miyakura, Hisanaga Horie, Yoshikazu Yasuda, Hirofumi Fujii, Kenjiro Kotake & Kokichi Sugano. (2014) The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks. Molecular Cancer Therapeutics 13:5, pages 1170-1180.
Crossref
Crossref
Tânia S. Morais & M. Helena Garcia. 2013. Advances in Organometallic Chemistry and Catalysis. Advances in Organometallic Chemistry and Catalysis
581
587
.
Giuseppe Giaccone & Jean-Charles SoriaPeter Stephens & Ruth Plummer. 2013. Targeted Therapies in Oncology, Second Edition. Targeted Therapies in Oncology, Second Edition
423
444
.
N J Curtin. (2013)
Inhibiting the
DNA
damage response as a therapeutic manoeuvre in cancer
. British Journal of Pharmacology 169:8, pages 1745-1765.
Crossref
Crossref
Anthony R. Gangloff, Jason Brown, Ron de Jong, Douglas R. Dougan, Charles E. Grimshaw, Mark Hixon, Andy Jennings, Ruhi Kamran, Andre Kiryanov, Shawn O’Connell, Ewan Taylor & Phong Vu. (2013) Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters 23:16, pages 4501-4505.
Crossref
Crossref
Marcie Weil, Shivaani Kummar, James Doroshow & Alice Chen. 2013. Handbook of Therapeutic Biomarkers in Cancer. Handbook of Therapeutic Biomarkers in Cancer
417
447
.
. 2013. DNA Repair and Cancer. DNA Repair and Cancer
113
114
.
Ana Isabel Tomaz, Tam?s Jakusch, T?nia S. Morais, Fernanda Marques, Rodrigo F.M. de Almeida, Filipa Mendes, ?va A. Enyedy, Isabel Santos, Jo?o Costa Pessoa, Tam?s Kiss & M. Helena Garcia. (2012) [RuII(?5-C5H5)(bipy)(PPh3)]+, a promising large spectrum antitumor agent: Cytotoxic activity and interaction with human serum albumin. Journal of Inorganic Biochemistry 117, pages 261-269.
Crossref
Crossref
. 2012. Cancer Biomarkers. Cancer Biomarkers
124
145
.
Rajkumar Venkatramani, Wayne L. Furman, Joerg Fuchs, Steven W. Warmann & Marcio H. Malogolowkin. (2012) Current and Future Management Strategies for Relapsed or Progressive Hepatoblastoma. Pediatric Drugs 14:4, pages 221-232.
Crossref
Crossref
Chun-Ho Park, Kwangwoo Chun, Bo-Young Joe, Jong-Hee Choi, Han-Chang Lee, Il-Whea Ku, Hyun Young Kim, Seong-Ho Koh, Goang Won Cho, Seung Hyun Kim & Myung-Hwa Kim. (2011) Synthesis and evaluation of thiopyrano[3,4-c]quinoline-9-carboxamide derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Medicinal Chemistry Research 21:8, pages 1533-1543.
Crossref
Crossref
Brian M. Alexander, Nancy Pinnell, Patrick Y. Wen & Alan D’Andrea. (2011) Targeting DNA repair and the cell cycle in glioblastoma. Journal of Neuro-Oncology 107:3, pages 463-477.
Crossref
Crossref
Arun Rajan, Corey A. Carter, Ronan J. Kelly, Martin Gutierrez, Shivaani Kummar, Eva Szabo, Mary Ann Yancey, Jiuping Ji, Baskar Mannargudi, Sukyung Woo, Shawn Spencer, William Douglas Figg & Giuseppe Giaccone. (2012) A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors. Clinical Cancer Research 18:8, pages 2344-2351.
Crossref
Crossref
Sophie Postel-Vinay, Elsa Vanhecke, Ken A. Olaussen, Christopher J. Lord, Alan Ashworth & Jean-Charles Soria. (2012) The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nature Reviews Clinical Oncology 9:3, pages 144-155.
Crossref
Crossref
D C Gilbert, A J Chalmers & S F El-Khamisy. (2011) Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. British Journal of Cancer 106:1, pages 18-24.
Crossref
Crossref
Majid Ali, Marzieh Kamjoo, Huw D. Thomas, Suzanne Kyle, Ivanda Pavlovska, Muhammed Babur, Brian A. Telfer, Nicola J. Curtin & Kaye J. Williams. (2011) The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice. Molecular Cancer Therapeutics 10:12, pages 2320-2329.
Crossref
Crossref
Shivaani Kummar, Alice Chen, Jiuping Ji, Yiping Zhang, Joel M. Reid, Matthew Ames, Lee Jia, Marcie Weil, Giovanna Speranza, Anthony J. Murgo, Robert Kinders, Lihua Wang, Ralph E. Parchment, John Carter, Howard Stotler, Larry Rubinstein, Melinda Hollingshead, Giovanni Melillo, Yves Pommier, William Bonner, Joseph E. Tomaszewski & James H. Doroshow. (2011) Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Research 71:17, pages 5626-5634.
Crossref
Crossref
Aswin Mangerich & Alexander Bürkle. (2010) How to kill tumor cells with inhibitors of poly(ADP‐ribosyl)ation. International Journal of Cancer 128:2, pages 251-265.
Crossref
Crossref
Barbara Vischioni, Nils H. Nicolay, Ricky A. Sharma & Thomas Helleday. 2011. Molecular Determinants of Radiation Response. Molecular Determinants of Radiation Response
143
171
.
Birija Sankar PatroBiswanath MaitySubrata Chattopadhyay. (2010) Topoisomerase Inhibitor Coralyne Photosensitizes DNA, Leading to Elicitation of Chk2-Dependent S-phase Checkpoint and p53-Independent Apoptosis in Cancer Cells. Antioxidants & Redox Signaling 12:8, pages 945-960.
Crossref
Crossref
Khurram Khan, Koji Araki, Daiyou Wang, Guayan Li, Xin Li, Jie Zhang, Weizheng Xu, Randall K. Hoover, Susan Lauter, Bert O'MalleyJrJr, Rena G. Lapidus & Daqing Li. (2009) Head and neck cancer radiosensitization by the novel poly(ADP‐ribose) polymerase inhibitor GPI‐15427. Head & Neck 32:3, pages 381-391.
Crossref
Crossref
Davide Melisi, Valeria Ossovskaya, Cihui Zhu, Roberta Rosa, Jianhua Ling, Patrick M. Dougherty, Barry M. Sherman, James L. Abbruzzese & Paul J. Chiao. (2009) Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity. Clinical Cancer Research 15:20, pages 6367-6377.
Crossref
Crossref
Terzah M. Horton, Gaye Jenkins, Debananda Pati, Linna Zhang, M. Eileen Dolan, Albert Ribes-Zamora, Alison A. Bertuch, Susan M. Blaney, Shannon L. Delaney, Madhuri Hegde & Stacey L. Berg. (2009)
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and
O
6
-methylguanine-DNA methyltransferase activity
. Molecular Cancer Therapeutics 8:8, pages 2232-2242.
Crossref
Crossref
Ruth Plummer, Christopher Jones, Mark Middleton, Richard Wilson, Jeffrey Evans, Anna Olsen, Nicola Curtin, Alan Boddy, Peter McHugh, David Newell, Adrian Harris, Patrick Johnson, Heidi Steinfeldt, Raz Dewji, Diane Wang, Lesley Robson & Hilary Calvert. (2008) Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research 14:23, pages 7917-7923.
Crossref
Crossref
Evan R. Guggenheim, Alison E. Ondrus, Mohammad Movassaghi & Stephen J. Lippard. (2008) Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorganic & Medicinal Chemistry 16:23, pages 10121-10128.
Crossref
Crossref
C Jones & E R Plummer. (2008) PARP inhibitors and cancer therapy ? early results and potential applications. The British Journal of Radiology 81:special_issue_1, pages S2-S5.
Crossref
Crossref
Xuesong Liu, Yan Shi, Ran Guan, Cherrie Donawho, Yanping Luo, Joann Palma, Gui-dong Zhu, Eric F. Johnson, Luis E. Rodriguez, Nayereh Ghoreishi-Haack, Ken Jarvis, Vincent P. Hradil, Milagros Colon-Lopez, Bryan F. Cox, Vered Klinghofer, Thomas Penning, Saul H. Rosenberg, David Frost, Vincent L. Giranda & Yan Luo. (2008) Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks. Molecular Cancer Research 6:10, pages 1621-1629.
Crossref
Crossref
Wilna J. Moree, Phyllis Goldman, Anthony J. Demaggio, Erik Christenson, Dan Herendeen, John Eksterowicz, Edward A. Kesicki, David L. McElligott & Graham Beaton. (2008) Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters 18:18, pages 5126-5129.
Crossref
Crossref
Jann N. Sarkaria, Gaspar J. Kitange, C. David James, Ruth Plummer, Hilary Calvert, Michael Weller & Wolfgang Wick. (2008) Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. Clinical Cancer Research 14:10, pages 2900-2908.
Crossref
Crossref
Thomas Helleday, Eva Petermann, Cecilia Lundin, Ben Hodgson & Ricky A. Sharma. (2008) DNA repair pathways as targets for cancer therapy. Nature Reviews Cancer 8:3, pages 193-204.
Crossref
Crossref
M J O'Connor, N M B Martin & G C M Smith. (2007) Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 26:56, pages 7816-7824.
Crossref
Crossref
Elizabeth Ruth Plummer & Hilary Calvert. (2007) Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy. Clinical Cancer Research 13:21, pages 6252-6256.
Crossref
Crossref
Susan Jones‐Bolin & Bruce Ruggeri. (2007) Metastatic Model of Colon Carcinoma in Mice: Utility in the Study of Tumor Growth and Progression. Current Protocols in Pharmacology 38:1.
Crossref
Crossref
Sheila Miknyoczki, Hong Chang, Jennifer Grobelny, Sonya Pritchard, Candace Worrell, Natalie McGann, Mark Ator, Jean Husten, James Deibold, Robert Hudkins, Allison Zulli, Ralph Parchment & Bruce Ruggeri. (2007) The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Molecular Cancer Therapeutics 6:8, pages 2290-2302.
Crossref
Crossref
Cherrie K. Donawho, Yan Luo, Yanping Luo, Thomas D. Penning, Joy L. Bauch, Jennifer J. Bouska, Velitchka D. Bontcheva-Diaz, Bryan F. Cox, Theodore L. DeWeese, Larry E. Dillehay, Debra C. Ferguson, Nayereh S. Ghoreishi-Haack, David R. Grimm, Ran Guan, Edward K. Han, Rhonda R. Holley-Shanks, Boris Hristov, Kenneth B. Idler, Ken Jarvis, Eric F. Johnson, Lawrence R. Kleinberg, Vered Klinghofer, Loren M. Lasko, Xuesong Liu, Kennan C. Marsh, Thomas P. McGonigal, Jonathan A. Meulbroek, Amanda M. Olson, Joann P. Palma, Luis E. Rodriguez, Yan Shi, Jason A. Stavropoulos, Alan C. Tsurutani, Gui-Dong Zhu, Saul H. Rosenberg, Vincent L. Giranda & David J. Frost. (2007) ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models. Clinical Cancer Research 13:9, pages 2728-2737.
Crossref
Crossref
Kapila Ratnam & Jennifer A. Low. (2007) Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology. Clinical Cancer Research 13:5, pages 1383-1388.
Crossref
Crossref
Derek Dunn, Jean Husten, Mark A. Ator & Sankar Chatterjee. (2007) Novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters 17:2, pages 542-545.
Crossref
Crossref
Ana Olmos, Rosa M. Giner & Salvador Máñez. (2006) Drugs modulating the biological effects of peroxynitrite and related nitrogen species. Medicinal Research Reviews 27:1, pages 1-64.
Crossref
Crossref
Richard H. Wilson. (2006) Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer. The Oncologist 11:9, pages 1018-1024.
Crossref
Crossref
Lucio Tentori, Carlo Leonetti, Marco Scarsella, Alessia Muzi, Emanuela Mazzon, Matteo Vergati, Olindo Forini, Rena Lapidus, Weizheng Xu, Annalisa Susanna Dorio, Jie Zhang, Salvatore Cuzzocrea, Grazia Graziani, Lucio Tentori, Carlo Leonetti, Marco Scarsella, Alessia Muzi, Emanuela Mazzon, Matteo Vergati, Olindo Forini, Rena Lapidus, Weizheng Xu, Annalisa Susanna Dorio, Jie Zhang, Salvatore Cuzzocrea & Grazia Grazia. (2006) Inhibition of poly(ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. The FASEB Journal 20:10, pages 1709-1711.
Crossref
Crossref
Susan Jones-Bolin, Hugh Zhao, Kathryn Hunter, Andres Klein-Szanto & Bruce Ruggeri. (2006) The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Molecular Cancer Therapeutics 5:7, pages 1744-1753.
Crossref
Crossref
David Martin-Oliva, Rocío Aguilar-Quesada, Francisco O'Valle, Jose Antonio Muñoz-Gámez, Rubén Martínez-Romero, Raimundo García del Moral, José Mariano Ruiz de Almodóvar, Raquel Villuendas, Miguel Angel Piris & F. Javier Oliver. (2006) Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis. Cancer Research 66:11, pages 5744-5756.
Crossref
Crossref
Gregory J. Wells, Ron Bihovsky, Robert L. Hudkins, Mark A. Ator & Jean Husten. (2006) Synthesis and structure–activity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorganic & Medicinal Chemistry Letters 16:5, pages 1151-1155.
Crossref
Crossref
Ming Tao, Chung Ho Park, Ron Bihovsky, Gregory J. Wells, Jean Husten, Mark A. Ator & Robert L. Hudkins. (2006) Synthesis and structure?activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters 16:4, pages 938-942.
Crossref
Crossref
Lisa M. Smith, Elaine Willmore, Caroline A. Austin & Nicola J. Curtin. (2005) The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks. Clinical Cancer Research 11:23, pages 8449-8457.
Crossref
Crossref
Trevor Hay, Helen Jenkins, Owen J. Sansom, Niall M.B. Martin, Graeme C.M. Smith & Alan R. Clarke. (2005)
Efficient Deletion of Normal
Brca2
-Deficient Intestinal Epithelium by Poly(ADP-Ribose) Polymerase Inhibition Models Potential Prophylactic Therapy
. Cancer Research 65:22, pages 10145-10148.
Crossref
Crossref
M R Bhonde, M-L Hanski, M Notter, B F Gillissen, P T Daniel, M Zeitz & C Hanski. (2005) Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene.
Crossref
Crossref
Haralabos Zorbas & Bernhard K. Keppler. (2005) Cisplatin Damage: Are DNA Repair Proteins Saviors or Traitors to the Cell?. ChemBioChem 6:7, pages 1157-1166.
Crossref
Crossref
E. Ruth Plummer, Mark R. Middleton, Christopher Jones, Anna Olsen, Ian Hickson, Peter McHugh, Geoffrey P. Margison, Gail McGown, Mary Thorncroft, Amanda J. Watson, Alan V. Boddy, A. Hilary Calvert, Adrian L. Harris, David R. Newell & Nicola J. Curtin. (2005)
Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes
O
6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1
. Clinical Cancer Research 11:9, pages 3402-3409.
Crossref
Crossref
Prakash Jagtap & Csaba Szabó. (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nature Reviews Drug Discovery 4:5, pages 421-440.
Crossref
Crossref
Sharon Marsh & Howard L McLeod. (2004) Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5:7, pages 835-843.
Crossref
Crossref
Maria Malanga & Felix R. Althaus. (2004) Poly(ADP-ribose) Reactivates Stalled DNA Topoisomerase I and Induces DNA Strand Break Resealing. Journal of Biological Chemistry 279:7, pages 5244-5248.
Crossref
Crossref